ES2654060T3 - Receptores de antígenos quiméricos anti-CD22 - Google Patents

Receptores de antígenos quiméricos anti-CD22 Download PDF

Info

Publication number
ES2654060T3
ES2654060T3 ES12781544.7T ES12781544T ES2654060T3 ES 2654060 T3 ES2654060 T3 ES 2654060T3 ES 12781544 T ES12781544 T ES 12781544T ES 2654060 T3 ES2654060 T3 ES 2654060T3
Authority
ES
Spain
Prior art keywords
car
seq
amino acid
cells
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12781544.7T
Other languages
English (en)
Spanish (es)
Inventor
Rimas J. ORENTAS
Crystal L. MACKALL
Ira H. Pastan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2654060T3 publication Critical patent/ES2654060T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
ES12781544.7T 2011-10-20 2012-10-19 Receptores de antígenos quiméricos anti-CD22 Active ES2654060T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549516P 2011-10-20 2011-10-20
US201161549516P 2011-10-20
PCT/US2012/061025 WO2013059593A1 (en) 2011-10-20 2012-10-19 Anti-cd22 chimeric antigen receptors

Publications (1)

Publication Number Publication Date
ES2654060T3 true ES2654060T3 (es) 2018-02-12

Family

ID=47143305

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12781544.7T Active ES2654060T3 (es) 2011-10-20 2012-10-19 Receptores de antígenos quiméricos anti-CD22

Country Status (11)

Country Link
US (1) US9868774B2 (enExample)
EP (1) EP2768863B1 (enExample)
JP (2) JP6267644B2 (enExample)
CN (2) CN109485730A (enExample)
AU (2) AU2012325915A1 (enExample)
BR (1) BR112014008849A2 (enExample)
CA (1) CA2851795C (enExample)
ES (1) ES2654060T3 (enExample)
IN (1) IN2014CN02906A (enExample)
RU (1) RU2644243C2 (enExample)
WO (1) WO2013059593A1 (enExample)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
IN2014CN02906A (enExample) * 2011-10-20 2015-07-03 Us Health
WO2013176915A1 (en) 2012-05-25 2013-11-28 Roman Galetto Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US11142563B2 (en) 2012-06-14 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified Fc region
US10072078B2 (en) 2012-10-24 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP2958942B1 (en) 2013-02-20 2020-06-03 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
KR102685501B1 (ko) 2013-02-20 2024-07-17 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
WO2014152177A1 (en) 2013-03-15 2014-09-25 Anthrogenesis Corporation Modified t lymphocytes
EP3623380B1 (en) 2013-03-15 2025-10-22 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
EP3004168A4 (en) 2013-05-24 2017-03-01 Board of Regents, The University of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN105722522B (zh) 2013-08-30 2021-10-19 得克萨斯大学体系董事会 用于肿瘤疗法的犬尿氨酸耗竭酶的施用
ES2960807T3 (es) 2013-10-11 2024-03-06 Us Health Anticuerpos contra TEM8 y su uso
US20160280798A1 (en) * 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN103589742A (zh) * 2013-11-07 2014-02-19 申峰 嵌合体抗原受体胞内段的基因及其编码蛋白
KR102551410B1 (ko) 2013-11-11 2023-07-04 추가이 세이야쿠 가부시키가이샤 개변된 항체 가변영역을 포함하는 항원 결합 분자
WO2015077789A2 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
JP6779785B2 (ja) 2013-12-19 2020-11-04 ノバルティス アーゲー ヒトメソテリンキメラ抗原受容体およびその使用
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CN106414748B (zh) 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
CN103820393B (zh) * 2014-02-24 2016-09-07 西比曼生物科技（上海）有限公司 工程化cd20靶向性的nkt细胞及其制备方法和应用
SG10202109752XA (en) 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
PH12016502010B1 (en) * 2014-04-10 2023-08-16 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Drug related transgene expression
TWI718992B (zh) 2014-07-21 2021-02-21 瑞士商諾華公司 使用cll-1嵌合抗原受體治療癌症
EP3172237A2 (en) 2014-07-21 2017-05-31 Novartis AG Treatment of cancer using humanized anti-bcma chimeric antigen receptor
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3174557B1 (en) * 2014-07-29 2018-10-17 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
TW202140557A (zh) 2014-08-19 2021-11-01 瑞士商諾華公司 使用cd123嵌合抗原受體治療癌症
US9975959B2 (en) 2014-08-29 2018-05-22 Board Of Regents, The University Of Texas System Administration of kynurenine depleting enzymes for tumor therapy
CA2959694C (en) 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
EP3193933B1 (en) 2014-09-17 2021-04-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd276 antibodies (b7h3)
MX2017003645A (es) 2014-09-17 2017-05-30 Novartis Ag Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
CN106973568B (zh) 2014-10-08 2021-07-23 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
EP3215534B1 (en) 2014-11-05 2020-04-15 Board of Regents, The University of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
AU2015343013B2 (en) 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
TWI880146B (zh) 2014-11-11 2025-04-11 日商中外製藥股份有限公司 包含經改變之抗體可變區之抗原結合分子的資料庫
US11266739B2 (en) 2014-12-03 2022-03-08 Juno Therapeutics, Inc. Methods and compositions for adoptive cell therapy
CN107207616B (zh) 2014-12-08 2021-11-19 美国卫生和人力服务部 抗cd70嵌合抗原受体
HRP20240357T1 (hr) 2014-12-24 2024-06-07 Autolus Limited Stanica
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
ES2869972T3 (es) 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
JP7264592B2 (ja) 2015-01-26 2023-04-25 ザ ユニバーシティー オブ シカゴ ＩＬ１３Ｒα２結合剤及び癌治療におけるその使用
SG11201706059SA (en) 2015-01-30 2017-08-30 Univ California Protein delivery in primary hematopoietic cells
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016130516A1 (en) 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
US10738116B2 (en) 2015-03-19 2020-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dual specific anti-CD22-anti-CD19 chimeric antigen receptors
DK3271389T3 (da) 2015-03-20 2020-04-27 Us Health Neutraliserende antistoffer mod gp120 og anvendelse deraf
IL254817B2 (en) 2015-04-08 2023-12-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
JP7114457B2 (ja) 2015-04-17 2022-08-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
GB201507111D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
ES2976647T3 (es) 2015-06-19 2024-08-06 Sebastian Kobold Proteínas de fusión PD-1-CD28 y su uso en medicina
CA2986604A1 (en) 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
WO2017035251A1 (en) 2015-08-25 2017-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cells modified to overexpress c-myb
WO2017040380A2 (en) 2015-08-28 2017-03-09 Research Development Foundation Engineered antibody fc variants
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
EP3347375B1 (en) * 2015-09-10 2020-12-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-cd276 chimeric antigen receptors
EP3359570A1 (en) 2015-10-07 2018-08-15 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
US11723922B2 (en) 2015-10-16 2023-08-15 Ludwig-Maximilians-Universität München CXCR6-transduced T cells for targeted tumor therapy
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
US11059879B2 (en) 2015-10-27 2021-07-13 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
MX2018006767A (es) 2015-12-04 2019-03-14 Novartis Ag Composiciones y metodos para oncologia inmunologica.
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
WO2017139199A1 (en) 2016-02-10 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible arginase
EP3423483B1 (en) 2016-03-02 2025-09-24 Board Of Regents Of the University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
CN105968210B (zh) * 2016-05-13 2019-05-31 深圳生创精准医疗科技有限公司 靶向cd22的强杀伤性嵌合抗原受体t细胞及其在制备治疗肿瘤的药物中的用途
CN106167527A (zh) * 2016-06-13 2016-11-30 长沙郝怡雅医药科技有限公司 一种融合蛋白
GB201610512D0 (en) * 2016-06-16 2016-08-03 Autolus Ltd Chimeric antigen receptor
BR112018077375A2 (pt) 2016-06-30 2019-10-01 F. Hoffmann-La Roche Ag kits, moléculas de anticorpo biespecífico trivalente, composição farmacêutica, vetor de expressão, célula hospedeira e método para a produção de uma molécula de anticorpo biespecífico trivalente
JP6908710B2 (ja) 2016-09-21 2021-07-28 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ケモカイン受容体ｃｃｒ４を標的にするキメラ抗原受容体（ｃａｒ）およびその使用
US11976299B2 (en) 2016-09-23 2024-05-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
AU2017336094A1 (en) 2016-09-29 2019-04-18 Immunitybio, Inc. HLA class I-deficient NK-92 cells with decreased immunogenicity
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
CN109983027A (zh) 2016-10-20 2019-07-05 细胞基因公司 基于cereblon的可异二聚化嵌合抗原受体
CN107964549B (zh) * 2016-10-20 2020-12-08 上海恒润达生生物科技有限公司 靶向cd22的嵌合抗原受体及其用途
EP3555266B1 (en) 2016-12-13 2023-11-15 The United States of America, as Represented by The Secretary, Department of Health and Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
IL267543B2 (en) 2017-01-06 2024-07-01 Immunitybio Inc Modified nk-92 cells and compositions thereof for use in the treatment of cancer and methods of preparation thereof
JP6706394B1 (ja) 2017-01-09 2020-06-03 レンティジェン・テクノロジー・インコーポレイテッドＬｅｎｔｉｇｅｎ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 抗メソセリン免疫療法によりがんを処置するための組成物および方法
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN110612119B (zh) 2017-02-07 2024-10-29 西雅图儿童医院（Dba西雅图儿童研究所） 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
EP4389226A3 (en) 2017-02-24 2024-12-18 MacroGenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
SG11201907922PA (en) * 2017-03-03 2019-09-27 Obsidian Therapeutics Inc Cd19 compositions and methods for immunotherapy
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
BR112019018124A2 (pt) 2017-03-22 2020-04-07 Intellia Therapeutics Inc composições e métodos para imunooncologia
EP4495141A3 (en) * 2017-03-27 2025-04-23 Noile-Immune Biotech, Inc. Chimeric antigen receptor
WO2018183842A1 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Standford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
US11944643B2 (en) 2017-03-31 2024-04-02 Cellectis Sa Universal anti-CD22 chimeric antigen receptor engineered immune cells
US11767512B2 (en) 2017-04-13 2023-09-26 Cellectis Sequence specific reagents targeting CCR5 in primary hematopoietic cells
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CA3062433A1 (en) 2017-05-15 2018-11-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors and their uses
EP3630980B1 (en) * 2017-06-01 2023-11-01 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cell preparation and uses thereof
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
WO2018226741A1 (en) 2017-06-05 2018-12-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T-cells modified to overexpress phf19
WO2018237325A1 (en) * 2017-06-22 2018-12-27 University Of Southern California Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers
US11235004B2 (en) 2017-06-30 2022-02-01 Innovative Cellular Therapeutics Holdings, Ltd. Lymphocyte cell lines and uses thereof
WO2019002633A1 (en) 2017-06-30 2019-01-03 Cellectis CELLULAR IMMUNOTHERAPY FOR REPETITIVE ADMINISTRATION
AU2018336791B2 (en) 2017-09-19 2025-08-21 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor T cell therapy and uses thereof
WO2019075055A1 (en) 2017-10-11 2019-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS
JP7275118B2 (ja) * 2017-10-16 2023-05-17 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ２２免疫療法によってがんを処置するための組成物および方法
KR102742741B1 (ko) * 2017-10-18 2024-12-16 프레시전 인코포레이티드 스페이서를 포함하는 폴리펩타이드 조성물
JP7585034B2 (ja) 2017-10-18 2024-11-18 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
WO2019084284A1 (en) 2017-10-27 2019-05-02 Coneksis, Inc. NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
US11952422B2 (en) 2017-12-05 2024-04-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
WO2019117976A1 (en) 2017-12-17 2019-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide hydrogels and use thereof
US12539308B2 (en) 2018-01-08 2026-02-03 The Trustees Of The University Of Pennsylvania Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
CN111670246A (zh) 2018-01-31 2020-09-15 南克维斯特公司 5%人白蛋白在洗涤和收获培养基中的用途
EP3749695A4 (en) 2018-02-06 2021-12-29 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CA3090512A1 (en) 2018-02-09 2019-08-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tethered interleukin-15 and interleukin-21
SG11202007622SA (en) 2018-02-11 2020-09-29 Memorial Sloan Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
KR20200130709A (ko) * 2018-03-06 2020-11-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 전립선-특이 막 항원 car 및 이의 사용 방법
CA3091224A1 (en) 2018-03-12 2019-09-19 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
EP3773912A1 (en) * 2018-04-10 2021-02-17 Amgen Inc. Chimeric receptors to dll3 and methods of use thereof
AU2019250692A1 (en) 2018-04-13 2020-11-05 Sangamo Therapeutics France Chimeric antigen receptor specific for Interleukin-23 receptor
EP3781179A4 (en) 2018-04-16 2022-11-09 Board of Regents, The University of Texas System HUMAN SEA KYNURENINA ENZYMES AND USES THEREOF
US12415845B2 (en) 2018-04-24 2025-09-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
CA3098450A1 (en) 2018-05-22 2019-11-28 Nantkwest, Inc. Basal media for growing nk-92 cells
US20210363484A1 (en) 2018-05-22 2021-11-25 Nantkwest, Inc. Optimization of nk-92 cell growth using poloxamer
IL321548A (en) 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
WO2020014029A1 (en) 2018-07-10 2020-01-16 Nantkwest, Inc. Generating cik nkt cells from cord blood
WO2020014245A1 (en) 2018-07-10 2020-01-16 Nantkwest, Inc. Cryopreservation
WO2020014482A1 (en) * 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
JP2021531808A (ja) 2018-08-01 2021-11-25 イミュニティーバイオ インコーポレイテッド 実証された標的に対する二次ホーミングの活性化を有する、ケモカイン応答性が活性化されたナチュラルキラー細胞
WO2020028654A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
IL314189A (en) 2018-08-01 2024-09-01 Immunitybio Inc A QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR OR A CYTOKINE, AND CHIMERIC ANTIGEN RECEPTOR FOR GENETIC MODIFICATION OF IMMUNOTHERAPIES- Expedited Examination
MX2021000827A (es) 2018-08-03 2021-03-25 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno que contiene dos dominios de union a antigeno que estan enlazados entre si.
CN109022363A (zh) * 2018-08-15 2018-12-18 马晓冬 一种基于PiggyBac载体的CD-133-CAR-T系统构建方法
US20200102370A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
JP2022501325A (ja) 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
CN112912396B (zh) 2018-10-22 2023-03-14 上海吉倍生物技术有限公司 抗cldn18.2抗体及其用途
AU2019375375B2 (en) 2018-11-06 2022-12-01 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
WO2020112669A1 (en) 2018-11-26 2020-06-04 Nantkwest, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
EP3670530A1 (en) 2018-12-18 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
CA3128971A1 (en) 2019-03-08 2020-09-17 Klinikum Der Universitat Munchen Ccr8 expressing lymphocytes for targeted tumor therapy
CA3144640A1 (en) 2019-06-24 2020-12-30 Children's Hospital Los Angeles Bcl11b overexpression to enhance human thymopoiesis and t cell function
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
EP3994173A1 (en) 2019-07-02 2022-05-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that bind egfrviii and their use
US20220281971A1 (en) * 2019-07-17 2022-09-08 National University Of Singapore Functional Binders Synthesized and Secreted by Immune Cells
AU2019459423B2 (en) 2019-08-01 2023-06-01 Immunitybio, Inc. Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells
US11058725B2 (en) 2019-09-10 2021-07-13 Obsidian Therapeutics, Inc. CA2 compositions and methods for tunable regulation
EP4032907A4 (en) 2019-09-20 2023-07-05 Shanghai Genbase Biotechnology Co., Ltd. Bcma-targeted antibody and chimeric antigen receptor
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
KR20220104217A (ko) 2019-11-26 2022-07-26 노파르티스 아게 Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
CA3163104A1 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
BR112022018105A2 (pt) 2020-03-10 2022-11-22 Massachusetts Inst Technology Métodos para gerar células nk tipo-memória modificadas e composições das mesmas
WO2021183207A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER
PE20230077A1 (es) 2020-03-31 2023-01-11 Chugai Pharmaceutical Co Ltd Moleculas de union al antigeno multiespecificas dirigidas a ligando de tipo delta 3 (dll3) y sus usos
AU2021250615A1 (en) * 2020-04-02 2022-12-01 Nanjing IASO Biotechnology Co., Ltd. Fully human anti-human CD22 chimeric antigen receptor and application thereof
CN111484562B (zh) * 2020-04-25 2021-08-20 首都医科大学附属北京朝阳医院 一种靶向cd22蛋白的抗体、嵌合抗原受体和药物
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
CN115715295A (zh) 2020-05-27 2023-02-24 安逊生物科学股份有限公司 将car t细胞重新定向到感兴趣的抗原的衔接分子
WO2022055946A1 (en) 2020-09-08 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
US20240018210A1 (en) 2020-11-13 2024-01-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
AU2021386370A1 (en) 2020-11-24 2023-06-22 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
MX2023006395A (es) 2020-12-03 2023-06-15 Century Therapeutics Inc Celulas dise?adas geneticamente y usos de estas.
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
WO2022183502A1 (zh) 2021-03-05 2022-09-09 上海吉倍生物技术有限公司 抗cldn6抗体及其用途
WO2022251070A1 (en) * 2021-05-27 2022-12-01 Innovative Cellular Therapeutics Holdings, Ltd. Modified chimeric antigen receptor and use thereof
US20250295693A1 (en) 2021-08-18 2025-09-25 Julius-Maximilians-Universität Würzburg Hybrid tumor/cancer therapy based on targeting the resolution of or inducing transcription-replication conflicts (trcs)
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
AU2022425620A1 (en) 2021-12-31 2024-07-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell therapy with vaccination as a combination immunotherapy against cancer
TW202340474A (zh) 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
CN118256444A (zh) * 2022-04-26 2024-06-28 深圳市体内生物医药科技有限公司 一种嵌合抗原受体t细胞及其制备方法和应用
US20240010742A1 (en) 2022-06-10 2024-01-11 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof
JP2026502616A (ja) * 2023-01-19 2026-01-23 ウーハン チャオチー バイオテクノロジー カンパニー リミテッド Ｃａｒ分子、それを含む細胞若しくはエクソソーム、及びそれらの使用
AU2024296940A1 (en) 2023-07-07 2026-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
WO2025160480A1 (en) 2024-01-26 2025-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
ES2300122T3 (es) 1997-03-20 2008-06-01 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Anticuerpos recombinantes e inmunoconjugados dirigidos contra celulas y tumores portadores de cd-22.
JP2004511425A (ja) 2000-02-08 2004-04-15 ザ　ペン　ステート　リサーチ　ファウンデーション 免疫療法に使用されるインターロイキン１３受容体サブユニットアルファー２
CA2425862C (en) * 2000-11-07 2013-01-22 City Of Hope Cd19-specific redirected immune cells
US7355012B2 (en) * 2001-09-26 2008-04-08 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
AU2004293471C1 (en) 2003-11-25 2011-02-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Mutated anti-CD22 antibodies and immunoconjugates
ES2776657T3 (es) * 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
PL3006457T3 (pl) 2005-07-29 2018-05-30 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Zmutowane egzotoksyny Pseudomonas o zmniejszonej antygenowości
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
PL2197903T3 (pl) 2007-09-04 2015-03-31 Us Gov Health & Human Services Delecje w domenie ii egzotoksyny a psuedomonas zmniejszające toksyczność niespecyficzną
WO2009124109A1 (en) 2008-04-04 2009-10-08 The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services Human monoclonal antibodies specific for cd22
WO2011032022A1 (en) 2009-09-11 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Improved pseudomonas exotoxin a with reduced immunogenicity
CA2776143A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
IN2014CN02906A (enExample) 2011-10-20 2015-07-03 Us Health

Also Published As

Publication number Publication date
WO2013059593A1 (en) 2013-04-25
JP2017212996A (ja) 2017-12-07
US9868774B2 (en) 2018-01-16
US20140274909A1 (en) 2014-09-18
RU2644243C2 (ru) 2018-02-08
IN2014CN02906A (enExample) 2015-07-03
AU2017225049A1 (en) 2017-09-28
CA2851795C (en) 2018-11-13
CA2851795A1 (en) 2013-04-25
CN103946242A (zh) 2014-07-23
AU2017225049B2 (en) 2019-08-08
RU2014118555A (ru) 2015-11-27
EP2768863A1 (en) 2014-08-27
CN109485730A (zh) 2019-03-19
JP2014534207A (ja) 2014-12-18
BR112014008849A2 (pt) 2017-09-12
EP2768863B1 (en) 2017-09-27
JP6267644B2 (ja) 2018-01-24
AU2012325915A1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
ES2654060T3 (es) Receptores de antígenos quiméricos anti-CD22
US11807682B2 (en) M971 chimeric antigen receptors
ES2876176T3 (es) Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
ES2875057T3 (es) Anticuerpos anti-CD276 (B7H3)
HK1213922B (en) M971 chimeric antigen receptors